29 August 2003 in FEBS Letters
1 October 2013 in Structure
1 April 2001 in Journal of Biological Chemistry
ABP57 is an auxin-binding protein that possesses receptor function. In this study, a protocol for ABP57 purification was developed on the basis of cross-reactivity shown between ABP57 and antisera raised against bovine serum albumin, which enabled us to purify ABP57 with a high yield and to further characterize it. ABP57 activates plant plasma membrane H+-ATPase (PM H+-ATPase) via direct interaction. The binding of indole-3-acetic acid (IAA) to the primary binding site on ABP57 caused a marked increase in the affinity of ABP57 for PM H+-ATPase, which was accompanied by a change in ABP57 conformation. Meanwhile, additional IAA binding to the secondary site on ABP57 nullified the initial effect without inducing further conformational change. When ABP57 with IAA occupying only the primary site interacted with PM H+-ATPase, no IAA could access the secondary site. These results suggest that IAA-induced biphasic alteration in the affinity of ABP57 for PM H+-ATPase correlates with a bell-shaped dose response of the enzyme to IAA. There is also a possibility that, whereas the stimulation phase of the response is associated with a conformational change of ABP57, the destimulation phase probably results from hindrance arising directly from the presence of IAA at the secondary site.
17 January 2023 in Journal of Clinical Investigation
In IgE-mediated food allergies, exposure to the allergen activates systemic allergic responses. Oral immunotherapy (OIT) treats food allergies through incremental increases in oral allergen exposure. However, OIT only induces sustained clinical tolerance and decreased basophil sensitivity in a subset of individuals despite increases in circulating allergen-specific IgG in all treated individuals. Therefore, we examined the allergen-specific antibodies from 2 OIT cohorts of patients with sustained and transient responses. Here, we compared antibodies from individuals with sustained or transient responses and discovered specific tolerance-associated conformational epitopes of the immunodominant allergen Ara h 2 recognized by neutralizing antibodies. First, we identified what we believe to be previously unknown conformational, intrahelical epitopes using x-ray crystallography with recombinant antibodies. We then identified epitopes only recognized in sustained tolerance. Finally, antibodies recognizing tolerance-associated epitopes effectively neutralized allergen to suppress IgE-mediated effector cell activation. Our results demonstrate the molecular basis of antibody-mediated protection in IgE-mediated food allergy, by defining how these antibodies disrupt IgE-allergen interactions to prevent allergic reactions. Our approach to studying the structural and functional basis for neutralizing antibodies demonstrates the clinical relevance of specific antibody clones in antibody-mediated tolerance. We anticipate that our findings will form the foundation for treatments of peanut allergy using neutralizing antibodies and hypoallergens.